Based on these findings, there are a significant lack on evidence regarding correlation between TILs (i.e., PD-1 and PD-L1) and outcome/response to ICIs in patients with metastatic CRPC because of the nature of prostate cancer, considering scarce TILs and low PD-L1 expressions. The gene discussed is CD274; the disease is prostate carcinoma.